Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06157892 · ClinicalTrials.gov registry record · Phase 2
A Study of Disitamab Vedotin With Other Anticancer Drugs in Solid Tumors
A Phase 2 study of Metastatic Breast Cancer and Breast Neoplasms, sponsored by Seagen, a wholly owned subsidiary of Pfizer.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 172
- Enrollment target
- 20
- Study locations
NCT06157892 is a Phase 2 study of Metastatic Breast Cancer and Breast Neoplasms that is actively recruiting participants, run by Seagen, a wholly owned subsidiary of Pfizer. The registered enrollment target is 172 participants, below the 204-participant average among 139 other Metastatic Breast Cancer trials with a reported enrollment target (16% lower). The trial reports 20 study locations across 6 states.
The verdict
NCT06157892, a Phase 2 study of Metastatic Breast Cancer and Breast Neoplasms, is actively recruiting participants, sponsored by Seagen, a wholly owned subsidiary of Pfizer.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 172 participants
- Enrollment target
- 20
- Study locations
Study Summary
This clinical trial is studying solid tumor cancers. A solid tumor is one that starts in part of your body like your lungs or liver instead of your blood. Once they've grown bigger in one spot or spread to other parts of the body, they're harder to treat. This is called advanced or metastatic cancer. Participants in this study must have breast cancer or gastric cancer. Participants must have tumors that have HER2 on them. This allows the cancer to grow more quickly or spread faster. There are few treatment options for patients with advanced or metastatic solid tumors that express HER2. This clinical trial uses an experimental drug called disitamab vedotin (DV). Disitamab vedotin is a type of antibody drug conjugate or ADC. ADCs are designed to stick to cancer cells and kill them. This clinical trial uses a drug called tucatinib, which has been approved to treat cancer in the United States and some other countries. This drug is sold under the brand name TUKYSA®. This study will test how safe and how well DV with tucatinib works for participants with solid tumors. This study will also test what side effects happen when participants take these drugs. A side effect is anything a drug does to the body besides treating the disease.
Conditions Studied
Interventions
- DRUG disitamab vedotin
- DRUG tucatinib
Study Locations (20)
Arizona
- Banner-University Medical Center Tucson Campus - Tucson
- Banner-University Medical Center Tucson Campus - Tucson
- The University of Arizona Cancer Center-North Campus Pharmacy, Attn: Kelly Myrdal - Tucson
- University of Arizona Cancer Center - North Campus - Tucson
- The University of Arizona Cancer Center-Main - Tucson
California
- UC Irvine Health - Chao Family Comprehensive Cancer Center - Orange
- UC Irvine Medical Center - Orange
- University of California, San Francisco | HDFCCC - Hematopoietic Malignancies - San Francisco
- UCLA Department of Medicine - Hematology & Oncology - Santa Monica
- UCLA Hematology/Oncology - Parkside - Santa Monica
Florida
- Moffitt Cancer Center - International Plaza - Tampa
- H. Lee Moffitt Cancer Center and Research Institute - Tampa
- Moffitt Cancer Center - McKinley Campus - Tampa
- Moffitt McKinley Hospital - Tampa
Colorado
- Colorado West Healthcare System, dba Community Hospital - Grand Junction
- Colorado West Healthcare, dba Grand Valley Oncology - Grand Junction
Connecticut
- Danbury Hospital - Danbury
- The Whittingham Cancer Center / Norwalk Hospital - Norwalk
District of Columbia
- Georgetown University Medical Center - Washington D.C.
- MedStar Georgetown University Hospital - Washington D.C.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 172 participants |
| Start Date | 2024-05-20 |
| Est. Completion | 2029-07-28 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06157892
The ClinicalTrials.gov registry entry for NCT06157892 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 172 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 204-participant average among 139 other Metastatic Breast Cancer trials with a reported enrollment target (16% lower). The listed sponsor is Seagen, a wholly owned subsidiary of Pfizer, which has 28 total studies on file at ClinicalTrials.gov.
The record links to 10 conditions, with Metastatic Breast Cancer appearing as the primary indexed condition, and to 2 interventions - of which disitamab vedotin is the first listed.
NCT06157892 reports 20 study locations spanning 6 distinct geographic areas - top geographies include Arizona, California, Florida.
Frequently Asked Questions
What is clinical trial NCT06157892 about?
NCT06157892 is a clinical study titled "A Study of Disitamab Vedotin With Other Anticancer Drugs in Solid Tumors". This clinical trial is studying solid tumor cancers. A solid tumor is one that starts in part of your body like your lungs or liver instead of your blood. Once they've grown bigger in one spot or spread to other parts of the body, they're harder to treat. This is called advanced or metastatic cancer...
What is the current status of trial NCT06157892?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 172 participants. The study started on 2024-05-20. Estimated completion is 2029-07-28.
What conditions does trial NCT06157892 study?
This clinical trial studies the following conditions: Metastatic Breast Cancer, Breast Neoplasms, Gastroesophageal Junction Adenocarcinoma, Advanced Breast Cancer, Triple Negative Breast Neoplasms.
What interventions are being tested in trial NCT06157892?
The interventions under investigation include: disitamab vedotin (DRUG), tucatinib (DRUG).
Who is sponsoring clinical trial NCT06157892?
This trial is sponsored by Seagen, a wholly owned subsidiary of Pfizer, which has 28 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06157892 being conducted?
This trial has 20 study locations across Arizona, California, Colorado, Connecticut, District of Columbia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Metastatic Breast Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Nurturing Exercise Routine for Greater Improvement in Zest and Energy on Enhertu
RECRUITING · Phase 2
-
Sequencing Antibody Drug Conjugates in ER+/HER2 LOW/ULTRA LOW MBC
RECRUITING · Phase 2
-
Sequential Therapies Modeled on Evolutionary Dynamics for Breast Cancer
RECRUITING · Phase 2
-
A Study of Surgery and Radiotherapy in People With Breast Cancer
RECRUITING · Phase 2
-
A Study of Enzalutamide, Enzalutamide in Combination With Mifepristone, or Chemotherapy in People With Metastatic Breast Cancer
RECRUITING · Phase 2
-
A Study of Radiation Therapy With Pembrolizumab and Olaparib or Other Radiosensitizers in Women Who Have Triple-Negative or Hormone-Receptor Positive/Her2 Negative Breast Cancer
RECRUITING · Phase 2
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.